[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100469860":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":28,"locations":35,"responsibleParty":53,"collaborators":33,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":33,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":33,"maxAge":33,"enrollmentInfo":63,"targetDuration":33,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":33,"overallStatus":37,"whyStopped":33,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Jonsson Comprehensive Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Diagnostic (image-guided biopsy)","EXPERIMENTAL","Patients undergo an image-guided biopsy at baseline and 2-4 weeks after cycle 2 of 177Lu-PSMA-617 therapy.",[13],"Procedure: Image Guided Biopsy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","Image Guided Biopsy","Undergo image-guided biopsy",[9],[21,22],"Image-Guided Biopsy","Imaging Guided Biopsy",[24],{"name":25,"affiliation":26,"role":27},"Johannes Czernin","UCLA \u002F Jonsson Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":33,"email":34},"Ankush Sachdeva","CONTACT","310-794-3421",null,"asachdeva@mednet.ucla.edu",[36],{"facility":26,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Los Angeles","California","90095","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-118.24368,34.05223,{"lat":47,"lon":46},[50,51],{"name":30,"role":31,"phone":32,"phoneExt":33,"email":34},{"name":52,"role":27,"phone":33,"phoneExt":33,"email":33},"Johannes Czernin, MD",{"type":54,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100469860","phase-1-image-guided-biopsies-to-identify-mechanisms-of-resistance-in-patients-with-metastatic-castration-resistant-prostate-cancer-treated-with-177lu-psma-radioligand-therapy-100469860",false,"NCT05398302","Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy","Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer to Identify Mechanisms of Resistance in Patients Undergoing 177Lu-PSMA Radioligand Therapy","Inclusion Criteria:\n\n* Volunteer patient\n* Histologically confirmed prostate cancer\n* Eligible for 177Lu-PSMA-617 under expanded access protocol (IRB# 21-5010) or as part of an approved trial\n* Based on positron emission tomography (PET)\u002Fcomputed tomography (CT) images: Evidence of lymph node or soft tissue metastatic disease amenable to image-guided biopsy\n* Platelets \\> 75,000\u002Ful within 14 days prior to biopsy\n* Prothrombin time (PT) or International normalized ratio (INR) and a partial thromboplastin time (PTT) \\\u003C 1.5 times the institutional upper limit normal (ULN) within 14 days prior to biopsy\n* Patients on warfarin, aspirin, or other anti-coagulants are eligible provided they are deemed able to tolerate discontinuation of anti-coagulation for one week prior to the biopsy. Conversion to low molecular weight heparin prior to biopsy is permitted per local standard operating procedures, provided there is agreement regarding the procedure between the treating physician, the interventional radiologist and the principal investigator (PI)\n\nExclusion Criteria:\n\n* Patients with significant congenital or acquired bleeding disorders (e.g. von Wildebrand's disease, acquired bleeding factor inhibitors) are not eligible","MALE",{"count":64,"type":65},30,"ESTIMATED","INTERVENTIONAL",[68],"PHASE1","This clinical trial studies mechanisms of resistance to 177-lutetium prostate specific membrane antigen (177Lu-PSMA) radioligand therapy using image-guided biopsies in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). Diagnostic procedures, such as image guided biopsies, may help in learning how well 177Lu-PSMA works to kill tumor cells and allow doctors to plan better treatment.",[71,72,73,74,75],"Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8","2026-06-11",{"date":78,"type":79},"2026-06-15","ACTUAL",{"date":81,"type":79},"2024-04-26",{"date":83,"type":65},"2027-12-31",{"name":5,"class":6},1]